Pages that link to "Q34656091"

The following pages link to Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group. (Q34656091):

Displaying 33 items.

• Emerging therapies for acute myeloid leukemia (Q33576363) (← links)
• Is there a standard induction regimen for patients with AML? (Q33952411) (← links)
• Recent advances in the treatment of acute myeloid leukemia. (Q34082437) (← links)
• Prognostic factors for intensive care unit admission, intensive care outcome, and post-intensive care survival in patients with de novo acute myeloid leukemia: a single center experience (Q34543008) (← links)
• Lessons from the past: opportunities to improve childhood cancer survivor care through outcomes investigations of historical therapeutic approaches for pediatric hematological malignancies (Q35667279) (← links)
• A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients (Q35886337) (← links)
• Comparison of carbon-sulfur and carbon-amine bond in therapeutic drug: 4β-S-aromatic heterocyclic podophyllum derivatives display antitumor activity (Q36129142) (← links)
• Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups (Q36727867) (← links)
• Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide (Q37201853) (← links)
• Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years (Q37271941) (← links)
• Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720. (Q37289691) (← links)
• Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: Practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation (Q37323006) (← links)
• Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. (Q37411669) (← links)
• Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia (Q37586897) (← links)
• Acute myeloid leukemia - strategies and challenges for targeting oncogenic Hedgehog/GLI signaling (Q37607838) (← links)
• Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Münster Study Group (Q37659087) (← links)
• Chemotherapy for patients with acute myeloid leukemia in first remission (Q37738440) (← links)
• Upfront therapy of acute myeloid leukemia. (Q37897183) (← links)
• The evolving landscape in the therapy of acute myeloid leukemia (Q38132064) (← links)
• Rapid upregulation of telomerase activity in human leukemia HL-60 cells treated with clinical doses of the DNA-damaging drug etoposide. (Q40728154) (← links)
• Mitoxantrone: a review of its pharmacological properties and use in acute nonlymphoblastic leukaemia (Q41120664) (← links)
• The FLAM regimen: revisiting time sequential induction therapy for patients with poor-risk acute myeloid leukemia (Q42943359) (← links)
• Intensified daunorubicin in induction therapy and autologous peripheral blood stem cell transplantation in postremission therapy (Double-7 protocol) for adult acute myeloid leukemia (Q44269630) (← links)
• Emerging therapeutic modalities for acute myeloid leukemia (AML) in older adults (Q46168137) (← links)
• Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literature (Q49840237) (← links)
• Chemotherapy protocols and incidence of oral mucositis. An integrative review. (Q55024194) (← links)
• Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML. (Q55472969) (← links)
• Nuclear transport inhibition in acute myeloid leukemia: recent advances and future perspectives (Q58555302) (← links)
• Dissecting causes for improved survival among patients with acute myeloid leukemia in two different eras receiving identical regimens in sequential randomized studies (Q58718483) (← links)
• A randomized study of the efficacy of postconsolidation therapy in adult acute nonlymphocytic leukemia: a report of the Italian Cooperative Group GIMEMA (Q68118557) (← links)
• Randomised unicenter trial for comparison of three regimens in de novo adult acute nonlymphoblastic leukaemia (Q77571485) (← links)
• Treatment of hematologic malignancies with alternate hemibody irradiation combined with high-dose chemotherapy: a single-center experience (Q81261922) (← links)
• Antibody Therapies for Acute Myeloid Leukemia: Unconjugated, Toxin-Conjugated, Radio-Conjugated and Multivalent Formats (Q92752934) (← links)